After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ionis Pharmaceuticals Inc is $6.80B. A total of 1.86 million shares were traded on the day, compared to an average of 1.91M shares.
In the most recent transaction, BENNETT C FRANK sold 10,000 shares of IONS for 43.98 per share on Aug 18 ’25. After the transaction, the EVP, Chief Scientific Officer now owns 93,466 company shares. In a previous transaction on Aug 18 ’25, BENNETT C FRANK bought 16,000 shares at 43.98 per share.
Among the insiders who sold shares, PARSHALL B LYNNE disposed of 5,000 shares on Aug 06 ’25 at a per-share price of $41.93. This resulted in the Director holding 86,344 shares of IONS after the transaction. In another insider transaction, Geary Richard S sold 10,000 shares at $42.86 per share on Aug 05 ’25. Company shares held by the EVP, Chief Development Officer now total 89,492.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, IONS has a high of $50.43 and a low of $23.95.
As of this writing, IONS has an earnings estimate of -$1.04 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$0.72 per share and a lower estimate of -$1.33. The company reported an EPS of -$0.72 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. IONS’s latest balance sheet shows that the firm has $2.11B in Cash & Short Term Investments as of fiscal 2021. There were $1.25B in debt and $240.55M in liabilities at the time. Its Book Value Per Share was $3.97, while its Total Shareholder’s Equity was $771.74M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 4.20.
